2024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza. InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the southern facility.
NEW YORK and HERZLIYA, Israel , Feb. 12, 2025 /PRNewswire/ -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr.
The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war. The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders.
13 Dec 2024 Date | | - Cons. EPS | - EPS |
23 May 2024 Date | | - Cons. EPS | - EPS |
1 Apr 2024 Date | | - Cons. EPS | - EPS |
28 Nov 2023 Date | | 0.03 Cons. EPS | - EPS |
21 Nov 2023 Date | | 0.03 Cons. EPS | - EPS |
13 Dec 2024 Date | | - Cons. EPS | - EPS |
23 May 2024 Date | | - Cons. EPS | - EPS |
1 Apr 2024 Date | | - Cons. EPS | - EPS |
28 Nov 2023 Date | | 0.03 Cons. EPS | - EPS |
21 Nov 2023 Date | | 0.03 Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Alexander Rabinovich CEO | NASDAQ (NMS) Exchange | M549GJ111 Cusip |
IL Country | 320 Employees | - Last Dividend | - Last Split | - IPO Date |
InterCure Ltd. is a prominent player in the medical cannabis industry, extending its footprint beyond its home country Israel to serve international markets. Founded in 1994 and based in Herzliya, Israel, the company has carved a niche in researching, cultivating, producing, and distributing pharmaceutical-grade cannabis and cannabis-based products tailored for medical applications. Besides its core operations in the cannabis sector, InterCure Ltd. also places strategic investments in the biomed sector, reflecting its broader vision in healthcare and medical innovations.